HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Kezar Life Sciences (NASDAQ:KZR) and maintained a $20 price target for the company's stock.
December 04, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Kezar Life Sciences and maintains a $20 price target.
The reiteration of a Buy rating and the maintenance of a $20 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on KZR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100